克隆性造血与多发性骨髓瘤移植后心血管病
这项回顾性队列研究纳入1036例接受首次自体造血细胞移植的多发性骨髓瘤患者,采用靶向测序检测克隆性造血(CHIP,变异等位基因频率≥2%)。CHIP与移植后5年心血管病风险独立相关(HR 2.72,95%CI 1.70-4.39),合并高血压或血脂异常者风险更高。
要点
- CHIP阳性者5年心血管病累积发生率为21.1%,阴性者为8.4%。
- CHIP与心衰(HR 4.02)、冠心病(HR 2.22)、卒中(HR 3.02)风险升高相关。
- CHIP合并高血压或血脂异常者心血管病风险分别约升高7倍和4倍。
核心结论
- 在接受造血细胞移植的多发性骨髓瘤患者中,CHIP与心血管病风险显著且独立相关。
- CHIP可能作为该人群心血管病的新型生物学标志物。
- CHIP合并心血管危险因素者心血管病风险极高。
研究设计与样本
- 回顾性队列研究,纳入2010至2016年在City of Hope综合癌症中心接受首次自体造血细胞移植的1036例多发性骨髓瘤患者。
- 利用移植前采集并冷冻保存的外周血干细胞产品进行靶向panel DNA测序检测CHIP,定义变异等位基因频率≥2%。
主要发现
- 201例(19.4%)检出至少1个CHIP变异,35例(3.4%)检出2个及以上变异。
- CHIP阳性者5年心血管病累积发生率为21.1%,阴性者为8.4%(P < .001);2个及以上变异者为25.6%。
- 多变量模型中CHIP与心血管病风险升高相关(HR 2.72;95%CI 1.70-4.39),其中心衰HR 4.02(95%CI 2.32-6.98)、冠心病HR 2.22(95%CI 1.06-4.63)、卒中HR 3.02(95%CI 1.07-8.52)。
- CHIP合并高血压者心血管病风险约升高7倍,合并血脂异常者约升高4倍(参照:无CHIP且无相应危险因素)。
临床怎么用
- 对拟行造血细胞移植的多发性骨髓瘤患者,可考虑检测CHIP以辅助心血管风险分层。
- 对CHIP阳性且合并高血压或血脂异常者,应加强心血管病监测与危险因素管理。
局限性
- 研究为单中心回顾性队列,结论外推需谨慎。
- 原文未报告CHIP相关心血管预防措施能否降低风险的干预性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a paucity of information on the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular disease (CVD) in patients with cancer, including those with multiple myeloma (MM) undergoing hematopoietic cell transplant (HCT), a population at high risk of developing CVD after HCT. OBJECTIVE: To examine the association between CHIP and CVD in patients with MM and to describe modifiers of CVD risk among those with CHIP. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of patients with MM who underwent HCT between 2010 and 2016 at City of Hope Comprehensive Cancer Center in Duarte, California, and had pre-HCT mobilized peripheral blood stem cell (PBSC) products cryopreserved and accessible for CHIP analyses. The study team performed targeted panel DNA sequencing to detect the presence of CHIP (variant allele frequency 2% or more). MAIN OUTCOMES AND MEASURES: The primary end point was the 5-year cumulative incidence and risk for developing de novo CVD (heart failure, coronary artery disease, or stroke) after HCT. RESULTS: Of 1036 consecutive patients with MM (580 male [56%]; median age, 60.0 years) who underwent a first autologous HCT, 201 patients had at least 1 CHIP variant (19.4%) and 35 patients had 2 or more variants (3.4%). The 5-year incidence of CVD was significantly higher in patients with CHIP (21.1% vs 8.4%; P < .001) compared with those without CHIP; the 5-year incidence among those with 2 or more variants was 25.6%. In the multivariable model, CHIP was associated with increased risk of CVD (hazard ratio [HR], 2.72; 95% CI, 1.70-4.39), as well as of individual outcomes of interest, including heart failure (HR, 4.02; 95% CI, 2.32-6.98), coronary artery disease (HR, 2.22; 95% CI, 1.06-4.63), and stroke (HR, 3.02; 95% CI, 1.07-8.52). Patients who had both CHIP and preexisting hypertension or dyslipidemia were at nearly 7-fold and 4-fold increased risk of CVD, respectively (reference: no CHIP, no hypertension, or dyslipidemia). CONCLUSION AND RELEVANCE: CHIP was significantly and independently associated with risk of CVD in patients with MM undergoing HCT and may serve as a novel biologically plausible biomarker for CVD in this cohort. Patients with MM and both CHIP and cardiovascular risk factors had an exceptionally high risk of CVD. Additional studies are warranted to determine if cardiovascular preventive measures can reduce CHIP-associated CVD risk.
引用
- Rhee JW, Pillai R, He T, et al. Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant. JAMA Cardiol. 2024. PMID: 37938837. doi:10.1001/jamacardio.2023.4105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。